167 related articles for article (PubMed ID: 28158999)
1. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
BMC Cancer; 2017 Feb; 17(1):97. PubMed ID: 28158999
[TBL] [Abstract][Full Text] [Related]
2. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE
Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698
[TBL] [Abstract][Full Text] [Related]
3. Association of the
Gallegos-Arreola MP; Márquez-Rosales MG; Sánchez-Corona J; Figuera LE; Zúñiga-González G; Puebla-Pérez AM; Delgado-Saucedo JI; Montoya-Fuentes H
Ann Clin Lab Sci; 2017 May; 47(3):291-297. PubMed ID: 28667029
[TBL] [Abstract][Full Text] [Related]
4. Impact of
Helwa R; Gansmo LB; Bjørnslett M; Halle MK; Werner HMJ; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Biomarkers; 2021 Jun; 26(4):302-308. PubMed ID: 33645339
[TBL] [Abstract][Full Text] [Related]
5. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
7. A case-control study on the SNP309T → G and 40-bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer.
Jalilvand A; Yari K; Aznab M; Rahimi Z; Salahshouri Far I; Mohammadi P
J Clin Lab Anal; 2020 Dec; 34(12):e23529. PubMed ID: 32951271
[TBL] [Abstract][Full Text] [Related]
8. Association between SNP309 and del1518 Polymorphism in MDM2 Homologue and Esophageal Squamous Cell Carcinoma Risk in Chinese Population of Shandong Province.
Zhang L; Zhu Z; Wu H; Wang K
Ann Clin Lab Sci; 2015; 45(4):433-7. PubMed ID: 26275695
[TBL] [Abstract][Full Text] [Related]
9. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
[TBL] [Abstract][Full Text] [Related]
10. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.
Ma H; Hu Z; Zhai X; Wang S; Wang X; Qin J; Jin G; Liu J; Wang X; Wei Q; Shen H
Cancer Lett; 2006 Aug; 240(2):261-7. PubMed ID: 16288830
[TBL] [Abstract][Full Text] [Related]
12. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women.
Kang S; Wang DJ; Li WS; Wang N; Zhou RM; Sun DL; Duan YN; Li SZ; Li XF; Li Y
Int J Gynecol Cancer; 2009 May; 19(4):572-7. PubMed ID: 19509552
[TBL] [Abstract][Full Text] [Related]
13. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
15. Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer: A meta-analysis of case-control studies.
Zhang J; Zhang Y; Zhang Z
Medicine (Baltimore); 2018 Jan; 97(2):e9554. PubMed ID: 29480845
[TBL] [Abstract][Full Text] [Related]
16. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
[TBL] [Abstract][Full Text] [Related]
17. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
18. SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.
Okamoto K; Tsunematsu R; Tahira T; Sonoda K; Asanoma K; Yagi H; Yoneda T; Hayashi K; Wake N; Kato K
BMC Med Genet; 2015 Aug; 16():67. PubMed ID: 26293665
[TBL] [Abstract][Full Text] [Related]
19. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.
Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195
[TBL] [Abstract][Full Text] [Related]
20.
Hua W; Zhang A; Duan P; Zhu J; Zhao Y; He J; Zhang Z
Onco Targets Ther; 2017; 10():3773-3780. PubMed ID: 28794641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
